TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20961701

Group type: EXPERIMENTAL
Intervention: Perifracture site injection (PI) with local anesthetic mixture (ropivacaine, morphine, epinephrine); n = 22.
Number of subjects: 44

Group type: COMPARATOR
Intervention: No perifracture site injection (no-PI); n = 22.
Number of subjects: 44
Study: 17585025

Group type: EXPERIMENTAL
Intervention: Low phytate maize
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal maize (Control)
Number of subjects: 53
Study: 12736155

Group type: EXPERIMENTAL
Intervention: l-arginine (1 g/min for 30 min) with insulin (6 mU x kg(‐1) x min(‐1) for 120 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: l-arginine (1 g/min for 30 min) without insulin
Number of subjects: 23

Group type: COMPARATOR
Intervention: d-arginine (1 g/min for 30 min)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: l-arginine with insulin (1.5 mU x kg(‐1) x min(‐1))
Number of subjects: 23
Study: 11050518

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg i.v. (group 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v. (group 2)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both droperidol and ondansetron (group 3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination therapy (droperidol + ondansetron)
Number of subjects: 90
Study: 10170301

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8289409

Group type: EXPERIMENTAL
Intervention: Soy-derived long-chain triglycerides (LCTs) emulsion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Long- and medium-chain triglycerides (MCTs/LCTs) emulsion
Number of subjects: 7
Study: 3755581

Group type: EXPERIMENTAL
Intervention: 1 alpha, 25‐dihydroxycholecalciferol (Rocaltrol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 alpha‐hydroxycholecalciferol (One‐Alpha)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28807536

Group type: EXPERIMENTAL
Intervention: Lockable household pesticide storage containers distributed to intervention households (20,457 containers).
Number of subjects: 223861

Group type: EXPERIMENTAL
Intervention: Lockable household pesticide storage containers (intervention).
Number of subjects: 223861

Group type: COMPARATOR
Intervention: Usual practice (control).
Number of subjects: 223861
Study: 26365210

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%, twice daily for 84 days
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo, twice daily for 84 days
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study: 23334069

Group type: EXPERIMENTAL
Intervention: Ponezumab 1 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ponezumab 3 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ponezumab 5 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ponezumab 10 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ponezumab (all doses)
Number of subjects: 15
Study: 21062338

Group type: EXPERIMENTAL
Intervention: Switching platform implants
Number of subjects: 14

Group type: COMPARATOR
Intervention: Traditional platform implants (control group)
Number of subjects: 14
Study: 19207079

Group type: EXPERIMENTAL
Intervention: Initial low-dose gentamicin with standard therapy (antistaphylococcal penicillin or vancomycin)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Initial low-dose gentamicin
Number of subjects: 236

Group type: COMPARATOR
Intervention: Daptomycin monotherapy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 236

Group type: COMPARATOR
Intervention: Antistaphylococcal penicillin
Number of subjects: 236
Study: 17213274

Group type: EXPERIMENTAL
Intervention: Troglitazone
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Lifestyle, metformin, or troglitazone
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: PPARG P12A genotype
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Body mass index and waist circumference
Number of subjects: 3548
Study: 15823765

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination tablet (Oxycodone 5 mg + Ibuprofen 400 mg)
Number of subjects: 36
Study: 11565840

Group type: EXPERIMENTAL
Intervention: TGF-β3 (25 μg/mL) applied as mouthwash four times daily
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 9692458

Group type: EXPERIMENTAL
Intervention: Heparin-coated bypass circuits
Number of subjects: 19

Group type: COMPARATOR
Intervention: Noncoated bypass circuits (Control)
Number of subjects: 19
Study: 7931456

Group type: EXPERIMENTAL
Intervention: VISI-CAARE
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional pen and paper
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VISI-CAARE 1.1
Number of subjects: 20
Study: 2972167

Group type: EXPERIMENTAL
Intervention: Danazol (200 mg 3 times daily)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High-dose Medroxyprogesterone Acetate (MPA, 100 mg daily)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31661809

Group type: EXPERIMENTAL
Intervention: Detoxification intervention (exercise, sauna-induced sweating, crystalline nicotinic acid, and other supplements)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Detoxification intervention
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 32
Study: 28434014

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg once daily for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nasal steroids and saline irrigation (control group)
Number of subjects: 60
Study: 25955397

Group type: EXPERIMENTAL
Intervention: NCP (80-kV and dual-phase scanning)
Number of subjects: 60

Group type: COMPARATOR
Intervention: RCP (120-kV and single-phase scanning)
Number of subjects: 60
Study: 24047312

Group type: EXPERIMENTAL
Intervention: Monitoring of renal function
Number of subjects: 35502

Group type: EXPERIMENTAL
Intervention: eGFR < 60 ml/min, proteinuria, and hypertension
Number of subjects: 35502
Study: 21411556

Group type: EXPERIMENTAL
Intervention: Facial skin color change (measured by ITA)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Sunscreen use
Number of subjects: 314

Group type: COMPARATOR
Intervention: Body mass index quartile comparison
Number of subjects: 314
Study: 19491183

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) prevention program consisting of 8 weekly, 90-minute group sessions followed by 6 monthly continuation sessions
Number of subjects: 316

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral (CB) prevention program
Number of subjects: 316
Study: 17944741

Group type: EXPERIMENTAL
Intervention: Informed of their negative H. pylori status
Number of subjects: 2708

Group type: COMPARATOR
Intervention: Placebo triple therapy
Number of subjects: 2708
Study: 15789980

Group type: EXPERIMENTAL
Intervention: Colgate 360 degrees toothbrush
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral-B Indicator toothbrush
Number of subjects: 82
Study: 11678487

Group type: EXPERIMENTAL
Intervention: Individualized dietary counseling to increase vegetable and fruit intake
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 53
Study: 9854116

Group type: EXPERIMENTAL
Intervention: 60 mg vesnarinone
Number of subjects: 3833

Group type: EXPERIMENTAL
Intervention: 30 mg vesnarinone
Number of subjects: 3833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3833
Study: 8209298

Group type: EXPERIMENTAL
Intervention: Cystic duct cholangiography (n = 38)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cholecystocholangiography (n = 31)
Number of subjects: 69
Study: 2589534

Group type: EXPERIMENTAL
Intervention: 2 mg im atropine (ATR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 30794228

Group type: EXPERIMENTAL
Intervention: Oxidized zirconium (OxZr) TKA
Number of subjects: 99

Group type: COMPARATOR
Intervention: Cobalt-chrome (CoCr) TKA
Number of subjects: 99
Study: 29793677

Group type: EXPERIMENTAL
Intervention: Topical application of umbilical cord blood platelet gel (CBPG), applied twice a week for 4 weeks and then once a week for an additional 4 weeks.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard wound care (control group).
Number of subjects: 20
Study: 25986314

Group type: EXPERIMENTAL
Intervention: Gastrotuss(®)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Maalox(®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22789423

Group type: EXPERIMENTAL
Intervention: Condylectomy with osteoarthrectomy and interposition with a temporalis muscle flap
Number of subjects: 22

Group type: COMPARATOR
Intervention: Condylectomy and osteoarthrectomy alone
Number of subjects: 22
Study: 21701239

Group type: EXPERIMENTAL
Intervention: Moderate intervention
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control
Number of subjects: 188
Study: 19170852

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 4174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4174
Study: 16553702

Group type: EXPERIMENTAL
Intervention: Nurse-initiated education programme
Number of subjects: 76
Study: 14744169

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 157
Study: 11410074

Group type: EXPERIMENTAL
Intervention: Petadolex (Petasites hybridus extract), 25 mg per capsule, 2 capsules twice daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 9274634

Group type: EXPERIMENTAL
Intervention: Chemical sunscreen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Physical sunscreen
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Chemical sunscreen with varying SPF
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subjects with lower skin types
Number of subjects: 25
Study: 1927240

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 0.1 mg fentanyl
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 0.1 mg fentanyl
Number of subjects: 91
Study: 6749447

Group type: EXPERIMENTAL
Intervention: ribavirin
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 30426256

Group type: COMPARATOR
Intervention: TR-RALP (traditional robot-assisted laparoscopic radical prostatectomy)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: RS-RALP (Retzius-sparing robot-assisted laparoscopic prostatectomy)
Number of subjects: 102
Study: 27939237

Group type: EXPERIMENTAL
Intervention: 24-month intervention including a 1-credit college course on healthy weight behaviors and a social networking website for support.
Number of subjects: 441

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: 24-month intervention (details as above).
Number of subjects: 441
Study: 26732420

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting, platinum-chromium PROMUS Element Plus stents
Number of subjects: 2683

Group type: EXPERIMENTAL
Intervention: Overall PE-Plus population
Number of subjects: 2683

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting, platinum-chromium PROMUS Element Plus stents in diabetic patients
Number of subjects: 2683
Study: 23405070

Group type: EXPERIMENTAL
Intervention: High fat/high energy shake
Number of subjects: 20

Group type: COMPARATOR
Intervention: Average breakfast shake
Number of subjects: 20
Study: 21057736

Group type: EXPERIMENTAL
Intervention: Stress management intervention (weeks 1-16)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Wait-list control (weeks 17-32)
Number of subjects: 102
Study: 19054193

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training for 1 hour twice a week for 13 weeks
Number of subjects: 269

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan training
Number of subjects: 269
Study: 16907703

Group type: EXPERIMENTAL
Intervention: Ser49Gly polymorphism of the beta1 ADR in hypertensive African-Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ser49Gly polymorphism of the beta1 ADR in hypertensive whites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arg389Gly polymorphism of the beta1 ADR in normotensive African-Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: beta1 haplotype (Ser49Gly-Arg389Gly) in hypertensive African-Americans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha2B C/A polymorphism in hypertensive whites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: alpha2B C/A polymorphism in both whites and African-Americans taking beta-blockers
Number of subjects: 0
Study: 15036054

Group type: EXPERIMENTAL
Intervention: Prefrontal TMS at 4 different stimulus intensities (60, 80, 100, and 120% of MT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Motor cortex TMS
Number of subjects: 9
Study: 11711728

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9654800

Group type: EXPERIMENTAL
Intervention: School-based alcohol and drug abuse prevention program
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 324
Study: 7995324

Group type: EXPERIMENTAL
Intervention: roxithromycin (300 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 3046299

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation at doses up to 3200 mg/d (3200 IU/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral vitamin E supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Animal studies of vitamin E
Number of subjects: 0
Study: 29651816

Group type: EXPERIMENTAL
Intervention: Weekly theoretical and hands-on guidance from dental hygienists on oral hygiene procedures and discussions on oral care routines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 25860384

Group type: EXPERIMENTAL
Intervention: Controlled local skin cooling (cryolysis)
Number of subjects: 0
Study: 24178765

Group type: EXPERIMENTAL
Intervention: Alcohol (vodka 37.5% at a dose of 46.5 g ethanol)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alcohol in combination with caffeine at a dose of 80 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alcohol in combination with energy drink at a dose of 250 ml
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 21175704

Group type: EXPERIMENTAL
Intervention: Generic omeprazole 20 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 24
Study: 18511540

Group type: EXPERIMENTAL
Intervention: Topical travoprost 0.004% once daily for 6 months
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 88
Study: 16970646

Group type: EXPERIMENTAL
Intervention: Mid-morning nutritional supplement for 3 weeks
Number of subjects: 30
Study: 14556728

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) 0.05-0.1 mg/kg per day
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 10890288

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Twelve-Step Facilitation therapy (TSF)
Number of subjects: 397
Study: 9562649

Group type: EXPERIMENTAL
Intervention: Sotalol (mean dose 240 mg q.d., max. 320 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (without sotalol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 17
Study: 7687736

Group type: EXPERIMENTAL
Intervention: Chart audit with feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 0
Study: 3571753

Group type: EXPERIMENTAL
Intervention: Desmopressin (20 micrograms; mean 0.3 micrograms/kg)
Number of subjects: 39
Study: 30012607

Group type: EXPERIMENTAL
Intervention: Ethanol intake
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD; 35 hours awake)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (PSD; four nights with 5 hours scheduled sleep)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Ethanol infusion
Number of subjects: 49
Study: 26708330

Group type: EXPERIMENTAL
Intervention: Universal disordered eating prevention program
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (n = 413 girls) from eleven schools in four neighboring towns
Number of subjects: 152
Study: 24374115

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 min, three intravenous infusions)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg over 45 min, second dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ECT (electroconvulsive therapy, administered on 3 test days every 48 hours)
Number of subjects: 18
Study: 24011296

Group type: EXPERIMENTAL
Intervention: Composite post restorations
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fiber post restorations
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reversed post restorations
Number of subjects: 54
Study: 21365332

Group type: EXPERIMENTAL
Intervention: Intravesical instillations with 40 ml chondroitin sulfate 0.2% solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no instillations)
Number of subjects: 20
Study: 18959492

Group type: EXPERIMENTAL
Intervention: Drug conservation (interrupt antiretroviral therapy until CD4(+) cell count <250 cells/microL)
Number of subjects: 5472

Group type: COMPARATOR
Intervention: Viral suppression (continued use of antiretroviral therapy)
Number of subjects: 5472
Study: 17161785

Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein ablation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Segmental pulmonary vein ablation
Number of subjects: 100
Study: 14567368

Group type: EXPERIMENTAL
Intervention: Ciclopirox gel 0.77% applied twice daily for 28 days
Number of subjects: 374

Group type: COMPARATOR
Intervention: Ciclopirox gel vehicle applied twice daily for 28 days
Number of subjects: 374
Study: 10912845

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) measurements using the Osteometer DTU-one (imaging) device
Number of subjects: 423

Group type: COMPARATOR
Intervention: Conventional non-imaging device (Walker-Sonix UBA575+)
Number of subjects: 423
Study: 8765259

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate 150 mg every 3 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral contraceptive (ethinyl estradiol 0.02 mg, desogestrel 0.15 mg) combined with oral danazol 50 mg a day for 21 days of each 28‐day cycle
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral contraceptive plus danazol
Number of subjects: 80
Study: 1389821

Group type: EXPERIMENTAL
Intervention: Mixed infusions of propofol and alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Separate infusions of propofol and alfentanil
Number of subjects: 40
Study: 6698659

Group type: COMPARATOR
Intervention: Mepindolol sulfate 2 X 2.5 mg daily
Number of subjects: 6
Study: 30724033

Group type: EXPERIMENTAL
Intervention: Gratitude writing
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Gratitude writing toward someone important
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Gratitude writing toward someone important (Study 3)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Gratitude writing toward own health (Study 3)
Number of subjects: 336
Study: 28929168

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80-mg every 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (switched to ixekizumab at Week 12)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept (switched to ixekizumab at Week 12)
Number of subjects: 0
Study: 27876027

Group type: EXPERIMENTAL
Intervention: Obesogenic risk assessment and personalized feedback on mealtime routines
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Responsive feeding curriculum, parenting curriculum, portion size guidance, obesogenic risk assessment, personalized feedback on mealtime routines, feeding curriculum counseling, goal setting, mobile messaging, and social support
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Social support component
Number of subjects: 107
Study: 24617961

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) administered via telemedicine, 10 weekly therapy sessions
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Telemedicine treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional face-to-face therapy
Number of subjects: 18
Study: 24308672

Group type: EXPERIMENTAL
Intervention: TXA-250 group (TXA 250 mg)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: TXA-500 group (TXA 500 mg)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (physiologic saline)
Number of subjects: 135
Study: 20692282

Group type: EXPERIMENTAL
Intervention: Individual counseling using motivational interviewing techniques for 6 months
Number of subjects: 0
Study: 19000558

Group type: EXPERIMENTAL
Intervention: Tablet formulation containing 1,000 mg levetiracetam
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control formulation (not explicitly named) containing 1,000 mg levetiracetam
Number of subjects: 18
Study: 15902986

Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerol (MCT) ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Carbohydrate (CHO) ingestion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MCT ingestion
Number of subjects: 8

Group type: COMPARATOR
Intervention: CHO ingestion
Number of subjects: 8
Study: 12915650

Group type: EXPERIMENTAL
Intervention: NGM/EE (180-250 microg of norgestimate and 35 microg of ethinyl estradiol)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45